QL1706 and Anlotinib Show Promise in Advanced Lung Cancer Phase II/III Trial
A phase II/III study is underway to evaluate QL1706 combined with anlotinib for advanced lung cancer.
Indication
Clinical and regulatory intelligence for Lung Cancer with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
AstraZeneca is conducting an observational study to evaluate AI's role in detecting pulmonary nodules and predicting lung cancer risk in high-risk individuals.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.